Abstract
The aim of this study was to investigate the efficacy and adverse effects of methotrexate (MTX) in the treatment of severe chronic asthma in 12 patients with severe asthma requiring continuous treatment with oral steroids at the Outpatient Department of Helsinki University Central Hospital. The study was a randomised, double-blind placebo-controlled trial of methotrexate treatment 15 mg weekly on a crossover basis over 24 weeks. During the 2 weeks baseline phase the mean dose of oral steroids administered was 10.9 (3.2–28) mg · day−1, and the mean dose of inhaled steroids administered was 2.3 (1.6–3.2) mg budesonide or beclomethasone. The average dose of oral steroids administered was 12.8 mg · day−1 during the last 2 placebo weeks but only 7.9 mg · day−1 during the last 2 weeks with MTX treatment. The reduction in daily dose of oral steroids was 38%, while daily bronchodilator use was reduced by 22%. During MTX treatment the patients experienced significantly less wheezing, dyspnoea and coughing. Nine out of 12 patients reported better asthma control during MTX treatment. The peak expiratory flow rate (PEF) 1-s forced expiratory volume (FEV1) values did not differ between MTX and placebo treatments. There was no statistical correlation between serum MTX concentration and clinical improvement. No serious adverse effects of MTX were found during the study. It was concluded that low-dose MTX may be beneficial for severe chronic asthma and that this therapy is well tolerated by patients.
Similar content being viewed by others
References
Cott GR, Cherniack RM (1988) Steroids and “steroid-sparing” agents in asthma. N Engl J Med 318: 634–636
Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel CE (1988) Methotrexate in the treatment of corticosteroid-dependent asthma. N Engl J Med 318: 603–607
Mullarkey MF, Lammert JK, Blumenstein BA (1990) Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med 112: 577–581
Shiner RJ, Nunn AJ, Chung KF, Geddes DM (1990) Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 336: 137–140
Dyer PD, Vaugham TR, Weber RW (1991) Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 88: 208–212
Geddes DM (1991) Methotexate in asthma. Clin Exp Allergy 21: 541–543
American Thoracic Society (1987) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136: 225–244
Malmberg LP, Hedman J, Sovijärvi ARA (1993) Accuracy and repeatability of a pocket turbine spirometer: comparison with a rolling seal flow-volume spirometer. Clinical Physiology 13: 89–98
Albertioni F, Pettersson B, Rask C, Seideman P, Peterson C (1995) Simultaneous quantitation of methotrexate and its two main metabolites in biological fluids by a novel solid-phase extraction using HPLC. J Chromatography Bx 665: 163–170
Erzurum SC, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, Martin RJ, Cott GR (1991) Lack of benefit of methotrexate in severe, steroid-dependent asthma. 114: 353–360
Coffey MJ, Sanders G, Eschenbacher WL, Tsien A, Ramesh S, Weber RW, Toews GB, McCune WJ (1994) The role of methotrexate in the management of steroid-dependent asthma. Chest 105: 117–121
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hedman, J., Steinus-Aarniala, B., Seideman, P. et al. Controlled trial of methotrexate in patients with severe chronic asthma. Eur J Clin Pharmacol 49, 347–349 (1996). https://doi.org/10.1007/BF00203775
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00203775